Other News To Note
Friday, March 11, 2011
MediGene AG, of Martinsreid, Germany, signed an exclusive license and supply agreement with Will-Pharma for commercialization and marketing of Veregen ointment for genital warts in Belgium, the Netherlands, and Luxembourg. It has existing agreements covering the U.S., other parts of Europe, Latin America and Asia. It will continue to pursue a global licensing strategy for the drug.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.